Therefore, a number of early-phase, dose-escalation/Phase I trials using different BET-inhibitor compounds covering most hematologic malignancies (including MM) have been completed or are currently underway28–34 (https://clinicaltrials.gov/ct2/results?term=bromodomain+inhibitor&Search=Search). The gene discussed is DNER; the disease is Miyoshi myopathy.